We use cookies to provide you with a better experience. By clicking the Accept button, you are agreeing to our use of cookies in accordance with our Privacy Policy.
  • Patient Resources
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
    • Glossary
  • Professional Resources
    • Research Center Profiles
    • Industry Provider Profiles
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
  • About Us
  • Contact Us
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » ChemoCentryx initiates phase II CCX140 trial

ChemoCentryx initiates phase II CCX140 trial

December 12, 2011
CenterWatch Staff

ChemoCentryx has initiatied a phase II clinical trial for CCX140, an orally-administered small molecule for the treatment of diabetic kidney disease (diabetic nephropathy). CCX140 is a novel CCR2 inhibitor with a pharmacological profile unlike that of other CCR2 compounds that have been known to be tested by other sponsors. CCX140 works by blocking the infiltration and activation of certain populations of monocyte and macrophages and other cells bearing CCR2 that occurs during inflammation. This mechanism of action provides selective treatment of the disease without compromising other immune functions.

As a precursor to the recently initiated clinical trials for CCX140 in patients with diabetic nephropathy, in an earlier phase II clinical trial, ChemoCentryx assessed the safety, tolerability and clinical effects of CCX140 in type 2 diabetics with normal kidney function. In that trial, CCX140 demonstrated clinical efficacy and successfully met its primary endpoint of safety and tolerability in type 2 diabetics on stable doses of metformin. Specifically, a statistically significant decrease in hemoglobin A1c (HbA1c) relative to placebo and a dose-dependent lowering of fasting plasma glucose were shown following only 28 days of treatment with CCX140. Additionally, ChemoCentryx's CCR2 inhibitors have shown to significantly improve kidney function and hyperglycemia in preclinical models of diabetic nephropathy in addition to those for type 2 diabetes.

The randomized, double-blind placebo controlled phase II study is designed
to evaluate the safety and tolerability of CCX140 in subjects with diabetic nephropathy. Other objectives are to study the efficacy of CCX140 versus placebo in changes from baseline in urinary albumin to creatinine ratio (ACR) and HbA1c. The trial is expected to enroll at least 135 subjects randomized to one of three treatment groups: placebo, 5 mg or 10 mg CCX140 once daily for a treatment duration of 12 weeks with a four-week follow-up period. Following an interim analysis for efficacy evaluation, the sample size may be increased to up to 270 patients, and/or dose groups may be added.

Global News Clinical Intelligence

Upcoming Events

  • 16Dec

    Master the Regulatory Pathway for Cell & Gene Therapy Submissions: Strategies for Successful BLAs

Featured Products

  • Regenerative-medicine-steps-to-accelerate-development-pdf

    Regenerative Medicine: Steps to Accelerate Development — PDF

  • Clinical-trial-agreements-a-guide-to-key-words-and-phrases-pdf

    Clinical Trial Agreements: A Guide to Key Words and Phrases — PDF

Featured Stories

  • Ich_logo

    ICH Overhauls 22-Year-Old Clinical Studies Guideline

  • Survey_chart2019

    Sponsors, CROs Doing Better, Sites Say, But More Work Is Needed

  • China-360x240

    U.S. Tops List of Trial Startups With China Making Progress in Phase 1

  • Phoneapp-360x240

    Device Apps Present Unique Risks in Trials

New!

2019 Site Survey Reports

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2019. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing